Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Manuel Gallén Castillo"'
Autor:
Emily K. Bergsland, Federico J. Vázquez-Mazón, Rocio Garcia-Carbonero, Carlos Becerra, Jim Cassidy, Donghua Yin, Tim Maughan, Manuel Gallén Castillo, Anne L. Thomas, Stephanie Green, Ramon Salazar, Timothy Iveson
Publikováno v:
Cancer Chemotherapy and Pharmacology. 73:695-702
Figitumumab (CP-751,871) is a human IgG2 monoclonal antibody that binds and down-regulates insulin-like growth factor receptor-1 (IGF-1R) and inhibits activation of this receptor by IGF-1 and IGF-2. This nonrandomized, open-label, single-arm, phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b57a27a3eacc49b6cd0d069d21e2060
https://doi.org/10.1007/s00280-014-2391-2
https://doi.org/10.1007/s00280-014-2391-2
Autor:
Gaspar Esquerdo Galiana, Emma Dotor Navarro, Pilar Escudero Emperador, Juan Manuel Campos Cervera, Inmaculada Guasch Jordan, Carles Pericay Pijaume, Manuel Gallén Castillo, Román Bastús Piulats, Eugeni Saigi Grau, Aleydis Pisa Gatell, Jordi Alfaro Gamero
Publikováno v:
Clinical and Translational Oncology. 13:61-66
Advanced pancreatic cancer has a bad prognosis, with a median overall survival (OS) no longer than 4-6 months. Since the end of last century, monotherapy with gemcitabine has remained the elective therapy, but new schedules are needed in order to imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8177e55c29933e03f4dcbef7e0c5815
https://doi.org/10.1007/s12094-011-0618-9
https://doi.org/10.1007/s12094-011-0618-9
Autor:
Manuel Gallén Castillo
Publikováno v:
Revista de Oncología. 3:328-329
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e88cd6d2d880f0537d375c7484f6116c
https://doi.org/10.1007/bf02718429
https://doi.org/10.1007/bf02718429